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Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression
may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who
reached a serum prostate-specific antigen (PSA) o4ngml
 1. Chemotherapy was suspended until a rise in PSAX50% and 1ngml
 1.
The median duration of treatment holiday was 20 weeks (13–43þweeks) and all patients retained sensitivity to re-treatment.
Chemotherapy holiday was associated with an improvement of fatigue (P¼0.05). Intermittent chemotherapy for AIPC is feasible and
deserves further study.
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Treatment for androgen-independent prostate cancer (AIPC) is
rapidly evolving. Chemotherapy with mitoxantrone and predni-
sone offers a palliative benefit but no survival advantage (Tannock
et al, 1996; Kantoff et al, 1999). Long-term therapy with this
regimen is not feasible due to cumulative dose-related cardio-
toxicity.
New regimens that have substantial activity in phase II studies
and are not associated with cumulative dose-related toxicities have
recently been developed. These include single-agent docetaxel;
combinations of estramustine with docetaxel, paclitaxel, etoposide,
and vinca alkaloids; multiagent chemotherapy; and combinations
of biologic agents with chemotherapy (Gilligan and Kantoff, 2002).
The optimal duration of chemotherapy for AIPC, particularly in
patients who have had a substantial response to treatment, remains
undefined. Most protocols call for treatment until progression.
This approach exposes some responding patients to uninterrupted
chemotherapy for prolonged periods of time. For example, the
median time to progression with docetaxel plus estramustine
treatment was 8 months for all patients and 10 months for patients
with measurable disease (Savarese et al, 2001).
Intermittent hormonal therapy is an approach that may limit the
chronic toxicity of this systemic treatment in prostate cancer
(Goldenberg et al, 1995; Higano et al, 1996) and is currently being
evaluated in randomised trials. Similarly, intermittent administra-
tion of chemotherapy for the treatment of AIPC may reduce
treatment-associated toxicity, but no data regarding this approach
are available.
In the context of a phase II clinical trial of high-dose calcitriol
and docetaxel in AIPC, we sought to develop and evaluate
prospectively an intermittent chemotherapy protocol. The ratio-
nale for calcitriol plus docetaxel has been previously described
(Beer et al, 2001). This report is focused on a detailed examination
of intermittent chemotherapy.
MATERIALS AND METHODS
Detailed eligibility criteria and treatment regimen have been
previously reported (Beer et al, 2001). Briefly, the study was IRB
approved and informed consent was obtained from all partici-
pants. Men with chemotherapy-naı ¨ve, metastatic AIPC were
treated with calcitriol (Rocaltrol
s 0.5mg capsules, Roche Pharma-
ceuticals, Nutley, NJ, USA) 0.5mg/kg on day 1 followed by
docetaxel (Taxotere
s, Aventis Pharmaceuticals, Bridgewater, NJ,
USA) 36mgm
 2 intravenously over 15–30min on day 2 of each
treatment week. Dexamethasone 8mg orally was given 12 and 1h
prior to and 12h after docetaxel. Treatment was administered
weekly for 6 consecutive weeks on an 8-week cycle.
To be eligible for intermittent chemotherapy, patients had to
meet criteria for prostate-specific antigen (PSA) response (50%
reduction confirmed 4 weeks apart) and had to have reached a
serum PSAo4ngml
 1. During the chemotherapy holiday, disease
status was monitored with a serum PSA and clinical examination
every 4 weeks and, in patients with measurable disease, by imaging
every 8 weeks. Quality of life (QOL) was assessed at the beginning
and at the end of the chemotherapy holiday by the EORTC core
questionnaire QLQ-C30 (Aaronson et al, 1993; Osoba et al, 1994)
obtained with permission from the EORTC (Brussels, Belgium).
Chemotherapy was resumed after a confirmed PSA increase of 50%
and of at least 1ngml
 1 or for any other evidence of disease
progression.
RESULTS
In total, 37 eligible patients were registered between May 2000 and
May 2001. In all, 30 patients met criteria for PSA response (Bubley
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let al, 1999). Of these, 11 reached confirmed serum PSA o
4ngml
 1. A comparison of pretreatment characteristics between
patients who became eligible for intermittent chemotherapy and
those who did not is shown in Table 1. The two groups differed
only by their baseline PSA concentrations.
Nine patients chose intermittent chemotherapy after receiving a
median of 45 weeks of chemotherapy (range 25–53 weeks). One
patient was excluded from the study for reasons unrelated to
prostate cancer or its treatment. Eight patients were therefore
evaluable for outcome with intermittent chemotherapy. The
median duration of treatment holiday was 20 weeks (range 13–
43þweeks). Seven patients resumed therapy, while one patient
remained on break after 43 weeks. In all patients, resumption of
treatment was triggered by a rising PSA. After resumption of
therapy, four patients met criteria for PSA response from their
postholiday PSA and three had stabilisation of the PSA for at least
12 weeks to date. With a median follow-up of 10.1 months from the
start of the chemotherapy holiday (and 20.4 months from study
entry), the median time to progression has not been reached. Two
patients had measurable disease. Both of these entered the break
after a partial response (PR) and retained PR status throughout the
treatment holiday.
The score for each QOL domain at the end of the break (or last
available in the one patient who remains on break) was compared
to the same at the beginning of the treatment holiday with each
patient serving as his own control. No difference in any of the
function scales of QLQ-C30 was found. Statistically significant
improvement in fatigue (p¼0.05 by paired t-test) was seen. A
trend (Pp0.1) towards improvement in dyspnoea, anorexia, and
diarrhoea and a trend towards a worsening in pain were observed.
All domains for which a difference with a P value p0.1 are shown
in Table 2.
DISCUSSION
While durable complete remission remains an elusive goal in the
treatment of AIPC, substantial responses to therapy are frequently
reported. In this trial, 30% of patients reached a PSAp4ngml
 1.
Regimens that omit anthracyclines, such as the one used in the
current study, are not associated with cumulative dose-related life-
threatening toxicity, but asthenia, oedema, neuropathy, hyperla-
crimation, onycholysis are just a few examples of toxicities that
typically increase with increasing duration of treatment.
This study demonstrates the feasibility of prospectively planned
intermittent chemotherapy in such patients. The duration of
chemotherapy holiday was clinically meaningful and no patient
progressed after chemotherapy was resumed. The QOL data,
although limited by sample size and lack of a control arm, suggest
meaningful improvements in common chronic toxicities of
chemotherapy with a treatment holiday. At the same time, a trend
towards increased pain was observed.
Larger studies are needed to further examine the potential
benefits and drawbacks of intermittent chemotherapy compared
with continuous chemotherapy. Based on the QOL data collected
in this study, one might speculate that in selected patients, the
intermittent approach may be associated with a reduction in the





intermittent therapy Total P-value
a
No. of patients 11 26 37 N/A
Age (years)
Median (range) 73 (46–82) 73 (62–83) 73 (46–83) 0.960
ECOG performance status
0 6 7 13 0.347





Median (range) 12 (6–553) 144 (20–921) 99 (6–921) 0.002
Site of metastases
Bone only 8 (73%) 14 (54%) 22 (59%) 0.481
Bone and lymph nodes 2 (9%) 10 (38%) 12 (32%)
Lymph nodes only 1 (18%) 2 (8%) 3 (8%)
Prior radiation
External beam to primary 5 (45%) 12 (46%) 17 (46%) 0.969
External beam to metastases 1 (9%) 7 (27%) 8 (22%) 0.229
Radiopharmaceuticals 0 (0%) 1 (4%) 1 (3%) 0.510
No. of prior hormonal treatments
Median (range) 2 (1–3) 2 (1–3) 2 (1–3) 0.618
aMann–Whitney U-test was used for comparison of continuous variable, w
2-test was used for comparison of categorical
variables. PSA¼prostate-specific antigen.










Fatigue 40.3723.0 27.8718.8 0.05
Pain 18.8724.3 27.1733.2 0.10
Dyspnoea 33.3730.9 12.5717.3 0.09
Anorexia 16.7725.2 4.2711.8 0.08
Diarrhoea 45.8735.4 29.2721.4 0.10
aTwo-sample, two-tailed t-test with a comparison between measurements before
and after the treatment holiday.
bHigher values for symptom scales indicate more of
the symptom. Within an individual patient, a change ofX10 points is thought to be
important because it is easily perceived by patients (Osoba et al, 1998, 1999).
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lchronic toxicity of chemotherapy. A larger sample size would be
necessary to determine if the observed reductions in chemotherapy
toxicity translate into improvements in overall QOL. The trend
towards an increase in pain suggests that intermittent chemother-
apy may not be desirable in patients who have significant levels of
prostate cancer-related pain and are receiving chemotherapy in
order to control pain.
This pilot study focused on feasibility and QOL. The impact of
intermittent chemotherapy on measures of cancer control, such as
time to progression and survival require further study. Similar to
ongoing debates about intermittent hormonal therapy, one might
speculate that intermittent application of chemotherapy could
hasten, delay, or have no effect on the time to emergence of
resistant disease. Randomised studies that compare intermittent to
continuous hormonal therapy are underway. A similar study of
chemotherapy should be considered.
Intermittent chemotherapy is feasible in AIPC patients. Addi-
tional study is needed to determine more definitively the
contribution of intermittent chemotherapy to the overall efficacy
and toxicity of treatment.
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